TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Multi-Center, Placebo- Controlled Study to Assess Prevention of Bone Loss by Treatment With GL701 (Prestara) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids
Brief Summary: The purpose of this clinical trial is to study the effects of GL701 on bone mineral density in women with active systemic lupus erythematosus (SLE) who are also receiving treatment with glucocorticoids (e.g., prednisone).


Options:
A: Arm Label: real drug; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dehydroepiandrosterone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Dehydroepiandrosterone; Assigned to Arm(s): real drug | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Intervention Type: DRUG; Name: Prasterone (GL701); Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Prasterone (GL701); Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Schizophrenia and Related Disorders in Children and Adolescents
Brief Summary: This study will evaluate the safety and efficacy of risperidone (Risperdal®), olanzapine (Zyprexa®), and molindone (Moban®) for the treatment of children and adolescents with schizophrenia or schizoaffective disorder.


Options:
A: Arm Label: olanzapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine (enrollment closed in this treatment) | Arm Label: risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone | Arm Label: molindone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Molindone | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): risperidone | Intervention Type: DRUG; Name: Olanzapine (enrollment closed in this treatment); Assigned to Arm(s): olanzapine | Intervention Type: DRUG; Name: Molindone; Assigned to Arm(s): molindone
B: Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A
C: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Family-aided Assertive Community Treatment; Type: EXPERIMENTAL; Interventions: Drug: aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine, Behavioral: Psychoeducational multifamily group treatment, Behavioral: Supported employment and education | Intervention Type: DRUG; Name: aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine; Assigned to Arm(s): Family-aided Assertive Community Treatment | Intervention Type: BEHAVIORAL; Name: Psychoeducational multifamily group treatment; Assigned to Arm(s): Family-aided Assertive Community Treatment | Intervention Type: BEHAVIORAL; Name: Supported employment and education; Assigned to Arm(s): Family-aided Assertive Community Treatment
D: Arm Label: In SHAPE; Type: EXPERIMENTAL; Interventions: Behavioral: In SHAPE, Behavioral: Fitness Club Membership | Arm Label: Fitness Club Membership; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Fitness Club Membership | Intervention Type: BEHAVIORAL; Name: In SHAPE; Assigned to Arm(s): In SHAPE | Intervention Type: BEHAVIORAL; Name: Fitness Club Membership; Assigned to Arm(s): Fitness Club Membership, In SHAPE

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Schizophrenia and Related Disorders in Children and Adolescents
Brief Summary: This study will evaluate the safety and efficacy of risperidone (Risperdal®), olanzapine (Zyprexa®), and molindone (Moban®) for the treatment of children and adolescents with schizophrenia or schizoaffective disorder.


Options:
A: Arm Label: Melatonin; Type: EXPERIMENTAL; Interventions: Drug: Melatonin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Melatonin; Assigned to Arm(s): Melatonin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: olanzapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine (enrollment closed in this treatment) | Arm Label: risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone | Arm Label: molindone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Molindone | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): risperidone | Intervention Type: DRUG; Name: Olanzapine (enrollment closed in this treatment); Assigned to Arm(s): olanzapine | Intervention Type: DRUG; Name: Molindone; Assigned to Arm(s): molindone
C: Arm Label: metformin 500 mg/d; clozapine 100 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin 500 mg, Drug: clozapine 100 mg | Arm Label: metformin 1000 mg/d; clozapine 100 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin 500 mg, Drug: clozapine 100 mg | Arm Label: placebo; clozapine 100 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: metformin 500 mg, Drug: clozapine 100 mg | Intervention Type: DRUG; Name: metformin 500 mg; Assigned to Arm(s): metformin 1000 mg/d; clozapine 100 mg, metformin 500 mg/d; clozapine 100 mg, placebo; clozapine 100 mg | Intervention Type: DRUG; Name: clozapine 100 mg; Assigned to Arm(s): metformin 1000 mg/d; clozapine 100 mg, metformin 500 mg/d; clozapine 100 mg, placebo; clozapine 100 mg
D: Arm Label: Olanzapine; Type: EXPERIMENTAL; Interventions: Drug: olanzapine, Behavioral: Wellness education | Arm Label: Olanzapine + Amantadine; Type: EXPERIMENTAL; Interventions: Drug: olanzapine, Drug: amantadine, Drug: metformin, Drug: zonisamide, Behavioral: Wellness education | Arm Label: Olanzapine + Metformin; Type: EXPERIMENTAL; Interventions: Drug: olanzapine, Drug: amantadine, Drug: metformin, Drug: zonisamide, Behavioral: Wellness education | Intervention Type: DRUG; Name: olanzapine; Assigned to Arm(s): Olanzapine, Olanzapine + Amantadine, Olanzapine + Metformin | Intervention Type: DRUG; Name: amantadine; Assigned to Arm(s): Olanzapine + Amantadine, Olanzapine + Metformin | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): Olanzapine + Amantadine, Olanzapine + Metformin | Intervention Type: DRUG; Name: zonisamide; Assigned to Arm(s): Olanzapine + Amantadine, Olanzapine + Metformin | Intervention Type: BEHAVIORAL; Name: Wellness education; Assigned to Arm(s): Olanzapine, Olanzapine + Amantadine, Olanzapine + Metformin

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Schizophrenia and Related Disorders in Children and Adolescents
Brief Summary: This study will evaluate the safety and efficacy of risperidone (Risperdal®), olanzapine (Zyprexa®), and molindone (Moban®) for the treatment of children and adolescents with schizophrenia or schizoaffective disorder.


Options:
A: Arm Label: olanzapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine (enrollment closed in this treatment) | Arm Label: risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone | Arm Label: molindone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Molindone | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): risperidone | Intervention Type: DRUG; Name: Olanzapine (enrollment closed in this treatment); Assigned to Arm(s): olanzapine | Intervention Type: DRUG; Name: Molindone; Assigned to Arm(s): molindone
B: Arm Label: Aripiprazole 10 mg/day Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole tablet, 10 mg | Arm Label: Aripiprazole 30 mg/day Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole tablet, 30 mg | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo tablet | Intervention Type: DRUG; Name: Aripiprazole tablet, 10 mg; Assigned to Arm(s): Aripiprazole 10 mg/day Group | Intervention Type: DRUG; Name: Aripiprazole tablet, 30 mg; Assigned to Arm(s): Aripiprazole 30 mg/day Group | Intervention Type: DRUG; Name: Placebo tablet; Assigned to Arm(s): Placebo Group
C: Intervention Type: DRUG; Name: Quetiapine Fumarate; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Phase III Multicenter Trial Of Gemcitabine In Combination With Carboplatin Or Paclitaxel Plus Carboplatin In Patients With Metastatic (Stage IIIB, IV) Non-Small Cell Lung Cancer
Brief Summary: RATIONALE: Drugs used in chemotherapy such as gemcitabine, carboplatin, and paclitaxel use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective in treating non-small cell lung cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of different combination chemotherapy regimens in treating patients who have stage IIIB, stage IV, or recurrent non-small cell lung cancer.


Options:
A: Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: gemcitabine hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): N/A
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Monotherapy (gemcitabine or vinorelbine) | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel + Carboplatin | Intervention Type: DRUG; Name: Paclitaxel + Carboplatin; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Monotherapy (gemcitabine or vinorelbine); Assigned to Arm(s): A
C: Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Pemetrexed, Drug: Carboplatin | Arm Label: Arm A:; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pemetrexed | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Arm A:, Arm B | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm B
D: Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: gemcitabine hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vinorelbine tartrate; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Single-Blind Study of Extracorporeal Photoimmune Therapy With UVADEX in Conjunction With Standard Therapy Alone for the Treatment of Patients With Corticosteroid-Refractory, Corticosteroid-Dependent, or Corticosteroid-Intolerant Chronic Graft-versus-Host Disease
Brief Summary: The purpose of this study is to determine whether extracorporeal photoimmune therapy with UVADEX (ECP) added to standard therapy is effective in the treatment of chronic graft-versus-host disease (GvHD).


Options:
A: Arm Label: Mycophenolate mofetil; Type: ACTIVE_COMPARATOR; Interventions: Drug: mycophenolate mofetil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: mycophenolate mofetil; Assigned to Arm(s): Mycophenolate mofetil | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Methoxsalen; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Extracorporeal Photopheresis; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Pentostatin; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Single-Blind Study of Extracorporeal Photoimmune Therapy With UVADEX in Conjunction With Standard Therapy Alone for the Treatment of Patients With Corticosteroid-Refractory, Corticosteroid-Dependent, or Corticosteroid-Intolerant Chronic Graft-versus-Host Disease
Brief Summary: The purpose of this study is to determine whether extracorporeal photoimmune therapy with UVADEX (ECP) added to standard therapy is effective in the treatment of chronic graft-versus-host disease (GvHD).


Options:
A: Intervention Type: DRUG; Name: Methoxsalen; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Extracorporeal Photopheresis; Assigned to Arm(s): N/A
B: Arm Label: Mycophenolate mofetil; Type: ACTIVE_COMPARATOR; Interventions: Drug: mycophenolate mofetil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: mycophenolate mofetil; Assigned to Arm(s): Mycophenolate mofetil | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): N/A
D: N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Control, Clinical Evaluation of Insulin Plus Rosiglitazone (2mg and 4mg) Compared to Insulin Plus Placebo for 24 Weeks in Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled on Insulin
Brief Summary: This 24-week study will compare the effects of adding the drug rosiglitazone (2mg and 4mg) or placebo to insulin in patients with Type 2 diabetes mellitus (non-insulin-dependent) who have not achieved their blood glucose goal using insulin alone. This study requires a total of seven visits during 28 weeks.


Options:
A: Arm Label: Saxagliptin, 5 mg + insulin; Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, 5 mg + insulin | Arm Label: Placebo + insulin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + insulin | Intervention Type: DRUG; Name: Saxagliptin, 5 mg + insulin; Assigned to Arm(s): Saxagliptin, 5 mg + insulin | Intervention Type: DRUG; Name: Placebo + insulin; Assigned to Arm(s): Placebo + insulin
B: Intervention Type: DRUG; Name: rosiglitazone; Assigned to Arm(s): N/A
C: Arm Label: Vildagliptin; Type: EXPERIMENTAL; Interventions: Drug: Vildagliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Vildagliptin; Assigned to Arm(s): Vildagliptin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Standard glycemic control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Arm Label: Intensive glycemic control; Type: EXPERIMENTAL; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Weight Loss Maintenance (WLM)
Brief Summary: To determine the effectiveness of continuous patient contact on weight loss maintenance.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: group sessions, Drug: sibutramine, orlistat, diethylpropion, Behavioral: Low Calorie Diet, Health One, Other: Intensive Medical Combination Therapy for Obesity | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Control Condition | Intervention Type: BEHAVIORAL; Name: group sessions; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: sibutramine, orlistat, diethylpropion; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Low Calorie Diet, Health One; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Intensive Medical Combination Therapy for Obesity; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Control Condition; Assigned to Arm(s): 2
B: Arm Label: E1; Type: EXPERIMENTAL; Interventions: Behavioral: Usual Care | Arm Label: A1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Individualized IC treatment | Intervention Type: BEHAVIORAL; Name: Individualized IC treatment; Assigned to Arm(s): A1 | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): E1
C: Arm Label: Personal contact (PC); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Personal contact (PC) | Arm Label: Interactive technology (IT); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Interactive technology (IT) | Intervention Type: BEHAVIORAL; Name: Personal contact (PC); Assigned to Arm(s): Personal contact (PC) | Intervention Type: BEHAVIORAL; Name: Interactive technology (IT); Assigned to Arm(s): Interactive technology (IT)
D: Arm Label: Lifestyle intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: control; Type: EXPERIMENTAL; Interventions: Other: control group | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle intervention | Intervention Type: OTHER; Name: control group; Assigned to Arm(s): control

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Weight Loss Maintenance (WLM)
Brief Summary: To determine the effectiveness of continuous patient contact on weight loss maintenance.


Options:
A: Arm Label: CHF patients, IVR-Enhanced Care; Type: EXPERIMENTAL; Interventions: Behavioral: IVR-Enhanced Care | Arm Label: COPD patients, IVR-Enhanced Care; Type: EXPERIMENTAL; Interventions: Behavioral: IVR-Enhanced Care | Arm Label: CHF patients, Usual Discharge Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: COPD patients, Usual Discharge Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: IVR-Enhanced Care; Assigned to Arm(s): CHF patients, IVR-Enhanced Care, COPD patients, IVR-Enhanced Care
B: Arm Label: Personal contact (PC); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Personal contact (PC) | Arm Label: Interactive technology (IT); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Interactive technology (IT) | Intervention Type: BEHAVIORAL; Name: Personal contact (PC); Assigned to Arm(s): Personal contact (PC) | Intervention Type: BEHAVIORAL; Name: Interactive technology (IT); Assigned to Arm(s): Interactive technology (IT)
C: Arm Label: Safety Training; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Safety Training | Arm Label: Personal Health Partner and Counseling (PHP+C); Type: EXPERIMENTAL; Interventions: Behavioral: Personal Health Partner and Counseling (PHP+C) | Intervention Type: BEHAVIORAL; Name: Safety Training; Assigned to Arm(s): Safety Training | Intervention Type: BEHAVIORAL; Name: Personal Health Partner and Counseling (PHP+C); Assigned to Arm(s): Personal Health Partner and Counseling (PHP+C)
D: Arm Label: Stepped Care; Type: EXPERIMENTAL; Interventions: Drug: Stepped care | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Stepped care; Assigned to Arm(s): Stepped Care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IV Study of Antiretroviral Therapy for HIV Infected Adults Presenting With Acute Opportunistic Infections: Immediate Versus Deferred Initiation of Antiretroviral Therapy
Brief Summary: The purpose of this study is to evaluate the effect of starting anti-HIV drugs in HIV infected patients who are being treated for opportunistic infections (OIs). This study will follow two patient groups: those who received anti-HIV drugs soon after being diagnosed with an OI and patients with OIs who deferred beginning anti-HIV drugs until after recovering from the OI.


Options:
A: Arm Label: Early antiretroviral therapy; Type: EXPERIMENTAL; Interventions: Other: Early antiretroviral therapy | Arm Label: Standard antiretroviral therapy; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Early antiretroviral therapy; Assigned to Arm(s): Early antiretroviral therapy
B: Intervention Type: DRUG; Name: Emtricitabine/tenofovir disoproxil fumarate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Lopinavir/ritonavir; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Stavudine; Assigned to Arm(s): N/A
C: Arm Label: Earlier HIV Therapy; Type: EXPERIMENTAL; Interventions: Drug: efavirenz, Biological: nucleoside | Arm Label: Deferred HIV Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: efavirenz, Biological: nucleoside | Intervention Type: DRUG; Name: efavirenz; Assigned to Arm(s): Deferred HIV Therapy, Earlier HIV Therapy | Intervention Type: BIOLOGICAL; Name: nucleoside; Assigned to Arm(s): Deferred HIV Therapy, Earlier HIV Therapy
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fluconazole, Drug: Fixed dose - Stavudine, lamivudine and Nevirapine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Fluconazole, Drug: Fixed dose - Stavudine, Lamivudine, Nevirapine | Intervention Type: DRUG; Name: Fluconazole; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Fixed dose - Stavudine, lamivudine and Nevirapine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Fixed dose - Stavudine, Lamivudine, Nevirapine; Assigned to Arm(s): 2

Answer: B